Complicated Skin And Skin Structure Infections Drugs Market Size Projected To Increase From $11.31 Billion To $16.6 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Complicated Skin And Skin Structure Infections Drugs Market Expansion From $11.31 Billion In 2026 To $16.6 Billion In 2030
The market for complicated skin and skin structure infection drugs has experienced robust expansion over recent years. Projected to rise from $10.36 billion in 2025 to $11.31 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 9.2%. Several factors have driven this historical increase, including a high prevalence of bacterial skin infections, heightened awareness of healthcare-associated infections, a rise in hospital admissions linked to CSSSI, the uptake of intravenous antibiotic treatments, and the availability of generic antibiotics.
The market for drugs targeting complicated skin and skin structure infections is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $16.61 billion, driven by a compound annual growth rate (CAGR) of 10.1%. This forecasted growth is fueled by several key factors, including the rise of multidrug-resistant bacteria, progress in targeted antibiotic therapies, the incorporation of digital health tools to manage infections, a growing preference for outpatient care options, and the broadening use of biologics along with innovative antimicrobial agents. Noteworthy trends expected during this period encompass an increasing frequency of antibiotic-resistant skin infections, the creation of new antibiotics tailored for deep tissue infections, the uptake of sophisticated drug delivery systems, greater rates of hospitalization and outpatient services for CSSSI, and a stronger emphasis on therapeutic approaches that prioritize patient needs.
Download A Free Sample Report For Comprehensive Market Insights:
Complicated Skin And Skin Structure Infections Drugs Market Industry Drivers: What Is Driving Revenue Growth?
The growing occurrence of skin diseases is anticipated to drive the expansion of the complicated skin and skin structure infections drugs market. Skin diseases refer to medical disorders that impact the skin’s appearance, structure, and function, potentially involving the skin, hair, nails, and associated tissues. To address resistant bacteria in cSSSI, a range of antibiotic drugs is utilized. Consequently, a higher incidence of skin disease may lead to new approvals for cSSSI drugs, enhance awareness, and promote earlier diagnosis of complicated skin and skin structure infections. For example, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that the average number of new melanoma skin cancer cases in the UK is projected to rise from roughly 20,800 cases during 2023-2025 to approximately 26,500 cases between 2038 and 2040. This suggests a forecasted 9% increase in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Hence, the rising prevalence of skin disease serves as a key driver for the growth of the complicated skin and skin structure infections drugs market.
Complicated Skin And Skin Structure Infections Drugs Market Segment Landscape: Which Areas Lead Market Development?
The complicated skin and skin structure infections drugs market covered in this report is segmented –
1) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Linezolid, Other Active Ingredients
2) By Route of Administration: Oral, Topical, Parenteral
3) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Delafloxacin: Delafloxacin Oral Tablets, Delafloxacin Injectable Form
2) By Vancomycin: Vancomycin Oral Solution, Vancomycin Injection
3) By Ceftaroline Fosamil: Ceftaroline Fosamil Injection
4) By Linezolid: Linezolid Oral Tablets, Linezolid Injectable Form
5) By Other Active Ingredients: Daptomycin, Tigecycline, Teicoplanin
Complicated Skin And Skin Structure Infections Drugs Market Growth Trends: What Is Influencing The Future Outlook?
Leading pharmaceutical companies within the complex skin and skin structure infections drug market are innovating with products like dalbavancin to secure a competitive advantage. Dalbavancin, a second-generation semi-synthetic lipoglycopeptide antibiotic, works by disrupting bacterial cell wall synthesis and effectively eliminating gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), rendering it beneficial for treating acute bacterial skin and skin structure infections (ABSSSI). For example, in January 2023, AbbVie Inc., a U.S.-based pharmaceutical firm, extended its approval for Xydalba (dalbavancin for injection) to pediatric patients across Europe. This intravenous therapy is designated for acute bacterial skin and skin structure infections in both adults and children aged three months and older. Key attributes include an extended half-life enabling infrequent administration, strong efficacy against resistant gram-positive pathogens, and a good safety profile, which helps clinicians effectively manage complex infections.
Complicated Skin And Skin Structure Infections Drugs Market Industry Leaders And Market Competition
Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy’s Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH
Access The Complete Complicated Skin And Skin Structure Infections Drugs Market Report:
Complicated Skin And Skin Structure Infections Drugs Market Global Footprint: Which Region Holds Market Leadership?
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 202. The regions covered in the complicated skin and skin structure infections drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
